Pub Date : 2025-11-01DOI: 10.1016/j.abd.2025.501220
Bárbara Fernandes Esteves , Maria Seabra Rato , João Carlos Almeida , Miguel Bernardes , Lúcia Costa , Raquel Miriam Ferreira
{"title":"Subacute skin lesions in systemic lupus erythematosus: an impressive and well-tolerated response to anifrolumab","authors":"Bárbara Fernandes Esteves , Maria Seabra Rato , João Carlos Almeida , Miguel Bernardes , Lúcia Costa , Raquel Miriam Ferreira","doi":"10.1016/j.abd.2025.501220","DOIUrl":"10.1016/j.abd.2025.501220","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 6","pages":"Article 501220"},"PeriodicalIF":3.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145413784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.abd.2025.501242
Ricardo Romiti , André V.E. de Carvalho , Juliana Nakano , Gleison V. Duarte , Grupo de Trabalho do Consenso Brasileiro de Psoríase da Sociedade Brasileira de Dermatologia
The 2024 Brazilian Consensus on Psoriasis and Treatment Algorithm of the Brazilian Society of Dermatology (SBD, Sociedade Brasileira de Dermatologia) comes four years after the release of the last Consensus, published in 2020. This new consensus now includes 43 chapters and has the participation of 85 professionals from across Brazil, including dermatologists and rheumatologists working in university hospitals, research centers, and public and private healthcare systems. The concept of Cumulative Life Course Impairment (CLCI), the inclusion of new biologics approved in Brazil after 2020, the update on psoriasis treatment in specific situations (such as pregnancy and surgery), and the discussion on "Response Predictors" are examples of updates addressed in this Consensus. The updated treatment algorithm used experts’ responses through the Delphi method and, among other modifications, removed acitretin from the plaque psoriasis treatment sequence, defined treatment lines for choosing immunobiologicals in both adult and pediatric populations, and included spesolimab and cyclosporine as first-line treatments for generalized pustular psoriasis. Finally, the new Consensus addresses the place of small molecule inhibitors in the algorithm and discusses future treatment options for plaque psoriasis.
巴西皮肤病学会（SBD, Sociedade Brasileira de Dermatologia）发布的2024年巴西银屑病共识和治疗算法是在2020年发布上一份共识的四年后发布的。这一新的共识现在包括43个章节，有来自巴西各地的85名专业人士参与，包括在大学医院、研究中心以及公共和私人医疗保健系统工作的皮肤科医生和风湿病学家。累积生命过程损害（CLCI）的概念，2020年后在巴西批准的新生物制剂的纳入，特定情况下（如妊娠和手术）牛皮癣治疗的更新以及关于“反应预测因子”的讨论是本共识中涉及的更新示例。更新后的治疗算法利用专家通过德尔菲法的反馈，除其他修改外，从斑块型银屑病治疗序列中删除了阿维素，定义了成人和儿童人群选择免疫生物制剂的治疗线，并将spesolimab和环孢素作为广泛性脓疱性银屑病的一线治疗方法。最后，新的共识解决了小分子抑制剂在算法中的地位，并讨论了斑块型银屑病的未来治疗选择。
{"title":"Highlights of the Brazilian Society of Dermatology’s Brazilian Consensus on Psoriasis","authors":"Ricardo Romiti , André V.E. de Carvalho , Juliana Nakano , Gleison V. Duarte , Grupo de Trabalho do Consenso Brasileiro de Psoríase da Sociedade Brasileira de Dermatologia","doi":"10.1016/j.abd.2025.501242","DOIUrl":"10.1016/j.abd.2025.501242","url":null,"abstract":"<div><div>The 2024 Brazilian Consensus on Psoriasis and Treatment Algorithm of the Brazilian Society of Dermatology (SBD, <em>Sociedade Brasileira de Dermatologia</em>) comes four years after the release of the last Consensus, published in 2020. This new consensus now includes 43 chapters and has the participation of 85 professionals from across Brazil, including dermatologists and rheumatologists working in university hospitals, research centers, and public and private healthcare systems. The concept of Cumulative Life Course Impairment (CLCI), the inclusion of new biologics approved in Brazil after 2020, the update on psoriasis treatment in specific situations (such as pregnancy and surgery), and the discussion on \"Response Predictors\" are examples of updates addressed in this Consensus. The updated treatment algorithm used experts’ responses through the Delphi method and, among other modifications, removed acitretin from the plaque psoriasis treatment sequence, defined treatment lines for choosing immunobiologicals in both adult and pediatric populations, and included spesolimab and cyclosporine as first-line treatments for generalized pustular psoriasis. Finally, the new Consensus addresses the place of small molecule inhibitors in the algorithm and discusses future treatment options for plaque psoriasis.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 6","pages":"Article 501242"},"PeriodicalIF":3.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.abd.2025.501213
Lanyu Sun , Mafalda Pinho , Cláudia Brazão , Joana Frade , Diogo de Sousa , Pedro de Vasconcelos , Luís Soares-de-Almeida , Paulo Filipe
Background
Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous sarcoma characterized by slow growth, a high local recurrence rate, and low metastatic potential. Objective: To characterize the clinicopathological features and the treatment outcomes of patients diagnosed with DFSP.
Methos
Retrospective study of patients with a histopathological diagnosis of DFSP between 1997 and 2022.
Results
Data from 42 patients with DFSP were included. The majority were female (69%) with a mean age of 49.1 years. The trunk (52%) and extremities (40%) were the most common tumor sites. Classic histologic pattern was observed in 90% of cases, while rare variants, including fibrosarcomatous, pigmented, and myxoid subtypes, were also identified. Wide local excision was the primary treatment (95%), achieving clear margins in 71% of patients. Local recurrence occurred in 4.8% and adjuvant radiotherapy was employed in 19% of cases. Two patients developed pulmonary metastases with disease progression despite treatment with imatinib.
Study limitations
Retrospective study based on medical and pathological records.
Conclusions
Cutaneous DFSP in this series demonstrated clinicopathologic features consistent with those reported in the literature, including a predilection for the trunk and middle-aged females. Histologically, most cases exhibited the classic storiform pattern with strong CD34 positivity. Wide local excision was the primary treatment modality, with a relatively low recurrence rate compared to the literature, possibly influenced by the use of adjuvant radiotherapy in select patients. Although uncommon, metastasis occurred in cases with recurrent disease and fibrosarcomatous transformation. Ongoing research into systemic therapies and molecularly targeted treatments is needed to improve outcomes in advanced DFSP.
{"title":"Clinicopathologic features and treatment outcomes of dermatofibrosarcoma protuberans: a 25-year retrospective study","authors":"Lanyu Sun , Mafalda Pinho , Cláudia Brazão , Joana Frade , Diogo de Sousa , Pedro de Vasconcelos , Luís Soares-de-Almeida , Paulo Filipe","doi":"10.1016/j.abd.2025.501213","DOIUrl":"10.1016/j.abd.2025.501213","url":null,"abstract":"<div><h3>Background</h3><div>Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous sarcoma characterized by slow growth, a high local recurrence rate, and low metastatic potential. <em>Objective:</em> To characterize the clinicopathological features and the treatment outcomes of patients diagnosed with DFSP.</div></div><div><h3>Methos</h3><div>Retrospective study of patients with a histopathological diagnosis of DFSP between 1997 and 2022.</div></div><div><h3>Results</h3><div>Data from 42 patients with DFSP were included. The majority were female (69%) with a mean age of 49.1 years. The trunk (52%) and extremities (40%) were the most common tumor sites. Classic histologic pattern was observed in 90% of cases, while rare variants, including fibrosarcomatous, pigmented, and myxoid subtypes, were also identified. Wide local excision was the primary treatment (95%), achieving clear margins in 71% of patients. Local recurrence occurred in 4.8% and adjuvant radiotherapy was employed in 19% of cases. Two patients developed pulmonary metastases with disease progression despite treatment with imatinib.</div></div><div><h3>Study limitations</h3><div>Retrospective study based on medical and pathological records.</div></div><div><h3>Conclusions</h3><div>Cutaneous DFSP in this series demonstrated clinicopathologic features consistent with those reported in the literature, including a predilection for the trunk and middle-aged females. Histologically, most cases exhibited the classic storiform pattern with strong CD34 positivity. Wide local excision was the primary treatment modality, with a relatively low recurrence rate compared to the literature, possibly influenced by the use of adjuvant radiotherapy in select patients. Although uncommon, metastasis occurred in cases with recurrent disease and fibrosarcomatous transformation. Ongoing research into systemic therapies and molecularly targeted treatments is needed to improve outcomes in advanced DFSP.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 6","pages":"Article 501213"},"PeriodicalIF":3.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.abd.2025.501215
Bruna Cristina Velozo , Michelle Venâncio Hong , Larissa Cassiano Bernardo , Meire Cristina Novelli e Castro , Jose Contreras-Ruiz , Luciana Patricia Fernandes Abbade
Pressure injuries must be identified and managed early to prevent them from becoming difficult to heal. In this review, the main complications inherent to pressure injuries will be highlighted, as well as the expected prognosis for patients with this health condition. Furthermore, the most current preventive measures are emphasized and supported by robust references from systematic reviews and guidelines. In the treatment section, an updated and comprehensive conceptual model is presented to guide dermatologists and healthcare professionals in assessing injuries in general, as well as pressure injuries. The focus on the debridement and management of infections and biofilm is emphasized. The importance of preparing the wound bed and the peri-wound area will also be addressed, unifying concepts with the best scientific evidence.
{"title":"Pressure Injuries: prevention, treatment, and complications – Part II","authors":"Bruna Cristina Velozo , Michelle Venâncio Hong , Larissa Cassiano Bernardo , Meire Cristina Novelli e Castro , Jose Contreras-Ruiz , Luciana Patricia Fernandes Abbade","doi":"10.1016/j.abd.2025.501215","DOIUrl":"10.1016/j.abd.2025.501215","url":null,"abstract":"<div><div>Pressure injuries must be identified and managed early to prevent them from becoming difficult to heal. In this review, the main complications inherent to pressure injuries will be highlighted, as well as the expected prognosis for patients with this health condition. Furthermore, the most current preventive measures are emphasized and supported by robust references from systematic reviews and guidelines. In the treatment section, an updated and comprehensive conceptual model is presented to guide dermatologists and healthcare professionals in assessing injuries in general, as well as pressure injuries. The focus on the debridement and management of infections and biofilm is emphasized. The importance of preparing the wound bed and the peri-wound area will also be addressed, unifying concepts with the best scientific evidence.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 6","pages":"Article 501215"},"PeriodicalIF":3.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.abd.2025.501225
Christina de Castro Brommonschenkel, Luciane Donida Bartoli Miot, Maria Cecília Valsechi Belli, Hélio Amante Miot
{"title":"Cohort study on the survival of methotrexate and acitretin treatment in patients with plaque psoriasis: experience from a single center","authors":"Christina de Castro Brommonschenkel, Luciane Donida Bartoli Miot, Maria Cecília Valsechi Belli, Hélio Amante Miot","doi":"10.1016/j.abd.2025.501225","DOIUrl":"10.1016/j.abd.2025.501225","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 6","pages":"Article 501225"},"PeriodicalIF":3.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.abd.2025.501239
María Olivares-Guerrero, Ana Jiménez-Sánchez, Mario Aparicio-Domínguez, Pablo Chicharro
{"title":"Effectiveness and safety of tralokinumab in a patient with severe atopic dermatitis and hepatitis B virus","authors":"María Olivares-Guerrero, Ana Jiménez-Sánchez, Mario Aparicio-Domínguez, Pablo Chicharro","doi":"10.1016/j.abd.2025.501239","DOIUrl":"10.1016/j.abd.2025.501239","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 6","pages":"Article 501239"},"PeriodicalIF":3.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145413648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.abd.2025.501227
Mariana de Figueiredo Silva Hafner , Ida Alzira Gomes Duarte , Bruna Cavaleiro de Macedo Souza , Rosana Lazzarini
{"title":"Reduction in chromium sensitization: a retrospective analysis from 2010 to 2024 in a dermatology allergy service","authors":"Mariana de Figueiredo Silva Hafner , Ida Alzira Gomes Duarte , Bruna Cavaleiro de Macedo Souza , Rosana Lazzarini","doi":"10.1016/j.abd.2025.501227","DOIUrl":"10.1016/j.abd.2025.501227","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 6","pages":"Article 501227"},"PeriodicalIF":3.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145463536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.abd.2025.501208
Kevin Yun Kim , Lung Wen Chao , Cyro Festa Neto
Teledermatology services in Brazil have a rich history, with several ongoing projects boosting academic research and providing efficiency gains by reducing waste, humanizing healthcare, and ensuring greater quality and speed in patient assistance. Reviewing the fundamentals and history of Teledermatology, along with the continuing evolution of Telemedicine services in Brazil and its practical aspects and future prospects, might bring better comprehension of how to further develop and improve these services.
{"title":"The history of Teledermatology and its evolution, practical aspects, and prospects in Brazil","authors":"Kevin Yun Kim , Lung Wen Chao , Cyro Festa Neto","doi":"10.1016/j.abd.2025.501208","DOIUrl":"10.1016/j.abd.2025.501208","url":null,"abstract":"<div><div>Teledermatology services in Brazil have a rich history, with several ongoing projects boosting academic research and providing efficiency gains by reducing waste, humanizing healthcare, and ensuring greater quality and speed in patient assistance. Reviewing the fundamentals and history of Teledermatology, along with the continuing evolution of Telemedicine services in Brazil and its practical aspects and future prospects, might bring better comprehension of how to further develop and improve these services.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 6","pages":"Article 501208"},"PeriodicalIF":3.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145386030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.abd.2025.501224
Christian Robles-Silva , Valentina Ross , Javier González , Alex Castro , Constanza Del Puerto
{"title":"Linear syringocystadenoma papilliferum: an unusual presentation in the inguinal region","authors":"Christian Robles-Silva , Valentina Ross , Javier González , Alex Castro , Constanza Del Puerto","doi":"10.1016/j.abd.2025.501224","DOIUrl":"10.1016/j.abd.2025.501224","url":null,"abstract":"","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 6","pages":"Article 501224"},"PeriodicalIF":3.6,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-18DOI: 10.1016/j.abd.2025.501210
Ana Carolina Putini Vieira , Maria Antônia Costa Cruz Akabane , Gianna Carolinne Graff Caletti , Kélen Klein Heffel , Amanda Tauana Oliveira e Silva
Background
Prurigo nodularis (PN) is a chronic, debilitating inflammatory skin disorder characterized by persistent itching, firm pruritic nodular lesions, and evidence of frequent scratching, like excoriation, and lichenification. Nemolizumab, a monoclonal antibody targeting IL-31, has shown significant improvements in skin lesions, itching, and sleep disturbances by reducing type 2 immune responses in PN.
Objectives
Evaluate the efficacy and safety of nemolizumab in treating PN by systematically analyzing randomized controlled trials (RCTs). Methods: The authors conducted a systematic review and meta-analysis by searching Pubmed, Embase, Cochrane Central and Scopus for RCTs comparing nemolizumab to placebo for PN. Statistical analysis usedR Studio 4.3.2.
Results
Three trials, involving 630 patients, were included. Nemolizumab significantly reduced pruritus at week-4 (MD = −32.04; 95% CI: −38.47, −25.62) and at week-16 (MD = −347.34; 95% CI: −1039.71, 345.04). Investigator’s Global Assessment (IGA) success favored Nemolizumab at week-16 (RR = 3.50; 95% CI: 2.18, 5.63). No significant differences were observed in adverse events (RR = 1.10; 95% CI: 0.97, 1.25) or serious adverse events (RR = 0.77; 95% CI: 0.43, 1.39). Nemolizumab also significantly reduced neurodermatitis.
Study limitations
Limitations include variability in treatment duration, small sample sizes, and the lack of direct comparisons with other biologics.
Conclusion
Our meta-analysis shows that Nemolizumab significantly improves pruritus, IGA success rates, and PAS > 75% in treating patients with moderate to severe PN. Its safety profile is favorable, with no significant differences in adverse events compared to placebo. These findings support Nemolizumab as a viable treatment for moderate to severe PN.
{"title":"Efficacy and safety of nemolizumab in prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials","authors":"Ana Carolina Putini Vieira , Maria Antônia Costa Cruz Akabane , Gianna Carolinne Graff Caletti , Kélen Klein Heffel , Amanda Tauana Oliveira e Silva","doi":"10.1016/j.abd.2025.501210","DOIUrl":"10.1016/j.abd.2025.501210","url":null,"abstract":"<div><h3>Background</h3><div>Prurigo nodularis (PN) is a chronic, debilitating inflammatory skin disorder characterized by persistent itching, firm pruritic nodular lesions, and evidence of frequent scratching, like excoriation, and lichenification. Nemolizumab, a monoclonal antibody targeting IL-31, has shown significant improvements in skin lesions, itching, and sleep disturbances by reducing type 2 immune responses in PN.</div></div><div><h3>Objectives</h3><div>Evaluate the efficacy and safety of nemolizumab in treating PN by systematically analyzing randomized controlled trials (RCTs). Methods: The authors conducted a systematic review and meta-analysis by searching Pubmed, Embase, Cochrane Central and Scopus for RCTs comparing nemolizumab to placebo for PN. Statistical analysis used<em>R</em> Studio 4.3.2.</div></div><div><h3>Results</h3><div>Three trials, involving 630 patients, were included. Nemolizumab significantly reduced pruritus at week-4 (MD = −32.04; 95% CI: −38.47, −25.62) and at week-16 (MD = −347.34; 95% CI: −1039.71, 345.04). Investigator’s Global Assessment (IGA) success favored Nemolizumab at week-16 (RR = 3.50; 95% CI: 2.18, 5.63). No significant differences were observed in adverse events (RR = 1.10; 95% CI: 0.97, 1.25) or serious adverse events (RR = 0.77; 95% CI: 0.43, 1.39). Nemolizumab also significantly reduced neurodermatitis.</div></div><div><h3>Study limitations</h3><div>Limitations include variability in treatment duration, small sample sizes, and the lack of direct comparisons with other biologics.</div></div><div><h3>Conclusion</h3><div>Our meta-analysis shows that Nemolizumab significantly improves pruritus, IGA success rates, and PAS > 75% in treating patients with moderate to severe PN. Its safety profile is favorable, with no significant differences in adverse events compared to placebo. These findings support Nemolizumab as a viable treatment for moderate to severe PN.</div></div>","PeriodicalId":7787,"journal":{"name":"Anais brasileiros de dermatologia","volume":"100 6","pages":"Article 501210"},"PeriodicalIF":3.6,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145326888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号